Second-Season RSV Immunization Worked for Eligible Children

(MedPage Today) -- WASHINGTON -- Real-world data backed the effectiveness of second-season nirsevimab (Beyfortus) immunizations against hospitalizations for children at high risk for severe respiratory syncytial virus (RSV) illness. In the case...